Aratana Therapeutics to Report First Quarter 2019 Financial Results

Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, will report financial results from the first quarter ended March 31, 2019 on Wednesday, May 8.

Recent News Posts

View All

Aratana Therapeutics’ Stockholders Adopt Merger Agreement with Elanco Animal Health

The Company reported 72% of the Company’s common stock outstanding as of the July 14, 2019 record date adopted the merger agreement and approximately 73% of the Company’s outstanding common stock as of the June 14, 2019 record date was present in person or represented by proxy at the Special Meeting. Of the shares voted, approximately 99% voted in favor of adopting the merger proposal.

Aratana Therapeutics Reports Voting Results from 2019 Annual Meeting of Stockholders

The Company announced voting results for the four proposals considered and voted upon by its stockholders at its Annual Meeting on June 6, 2019. The Company reported 44,510,117 shares of common stock present in person or represented by proxy at the Annual Meeting, which represents approximately 91% of the Company’s outstanding common stock as of the April 10, 2019 record date.